Furthermore, a novel combination therapy comprising an RAF/MEK inhibitor CH5126766 (VS-6766) and eribulin has been demonstrated to potently inhibit TNBC cell line growth by inducing apoptosis and simultaneously suppressing the expression of the programmed cell death ligand 1 (PD-L1), with significant reduction in tumour growth in vivo [99] (Figure 4). Here, CD274 is linked to neoplasm.